Navigation Links
Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
Date:12/14/2009

hers, the inherent uncertainty associated with financial projections; successful integration of the Arrow acquisition and the ability to recognize the anticipated synergies and benefits of the Arrow acquisition; the impact of competitive products and pricing; the difficulty of predicting the timing or outcome of litigation; variability of revenue mix between the Company's Brand, Generic and Distribution business units; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; timely and successful consummation and implementation of strategic initiatives; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the uncertainty associated with the identification and successful consummation of external business development transactions; market acceptance of and continued demand for Watson's products; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson's and its third party manufacturers' facilities, products and/or businesses; uncertainties related to the timing and outcome of litigation and other claims; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on Form 10-Q for the period ended September 30, 2009. Except a
'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Present at Credit Suisse Healthcare Conference
8. Watson Files FDA Application for Generic Rozerem(R)
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/gbd3bt/stability_testing ... Testing of Pharmaceuticals (London, UK - December 2-3, 2015)" ... this comprehensive two day seminar delegates will: ... are suitable for global arketing - Be able ... samples and facilities - Know how to save ...
(Date:9/3/2015)... MUMBAI, India , Sept. 3, 2015  Cipla, ... to meet the everyday needs of all patients, today ... into definitive agreements to acquire two US-based companies, InvaGen ... subject to certain closing conditions, is valued at $550 ... combined revenue from these transactions is over $200 million ...
(Date:9/3/2015)... With a population of more than 1 ... also its single largest potential market for goods and ... all major world economies in the average rate of ... health expenditures. As an in vitro diagnostics (IVD) market, ... United States, western European countries, and Japan. China represents ...
Breaking Medicine Technology:Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2Cipla to acquire 100% of generic businesses in US for $550M 2Cipla to acquire 100% of generic businesses in US for $550M 3Cipla to acquire 100% of generic businesses in US for $550M 4Cipla to acquire 100% of generic businesses in US for $550M 5IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13
... SILVER SPRING, Md., May 6, 2011 The U.S. Food ... allow a new group of patients at risk of stroke ... RX Acculink carotid stent. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... neck bring blood to the brain. The blood flow in ...
... BEACH, Calif., May 6, 2011 Yesterday, the ... Novartis drug Afinitor® (everolimus) for the treatment of ... less than five percent of all pancreatic cancer ... aggressive than the more common form of pancreatic ...
Cached Medicine Technology:FDA Expands Approved Use For Carotid Stent 2FDA Expands Approved Use For Carotid Stent 3FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors 2
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, ... devices, announced its only mission and research focus: Water Life Science®. In the ... body water evaporation is becoming dangerously accelerated. As a result of the global ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for the ... October 9-10, 2015 at the Diplomat Resort & Spa has been announced and ... researchers at the top of their field and will be presenting sessions such ...
(Date:9/4/2015)... Seattle, Washington (PRWEB) , ... September 04, 2015 ... ... the design and development of its first neighborhood created specifically for adults with ... located in the Phoenix Metro area and feature 30 cottage or “pocket” homes. ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... Benker Residence in South Glastonbury, Connecticut, has been selected for the Residential Award ... significant energy efficiency and resiliency measures. Chosen from a highly competitive field of ...
(Date:9/4/2015)... ... ... Overseer at The House of Yahweh, has written an open letter to Pope Francis that ... States. , Yisrayl lays out what he says is the true meaning of the Pope’s ... the meaning of his own name and describes what bible prophecy says about his own ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
... individual is born in may play a role in determining ... nervous system disorder multiple sclerosis.// ,Results showed people ... while people born in November are at lowest risk. Those ... those with November birthdays. Conversely people born in November were ...
... rise. Worldwide, most children with cancer live in developing ... countries are 80 percent, while most children in developing ... ,Researchers analyzed data from 63 European, population-based cancer ... were recorded for virtually all tumor types in children. ...
... lumpectomy may be safe for breast cancer patients say ... Standard treatment for women with breast cancer usually involves ... surgery , however for most women the length of ... them to choose mastectomy instead of breast conservation. ...
... new study reveals the steps you take to prevent ... dementia. //According to researchers, risk factors like high blood ... vessels in the brain and can cause death of ... medical studies on drugs designed to slow the progression ...
... shows hydrotherapy, or water exercise, may improve strength and mobility ... than age 50 were involved in the study. Patients were ... a week in a swimming pool, the second exercised in ... Both the water and gym programs focused on resistance exercises. ...
... study researchers say the drug clodronate is an effective treatment ... bones. Researchers studied more than 1,000 patients // with breast ... clodronate a day or a placebo for five years. ... cancer spread to their bones. Fifty-one of these patients were ...
Cached Medicine News:
... E+ is a precision rotary ... advance with manual cutting. The ... easy to operate. Coarse Advance ... option of manually advancing the ...
The Shandon Cryotome E Cryostat model features an automated, precise electronic specimen advance system....
... Netmon remote monitoring service allows the ... and monitored from any location via ... service enhances preventive maintenance capabilities. ... the unit (with your permission) from ...
Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains....
Medicine Products: